text:  Lots of the qualms against approval had less to do with MDMA itself than they had to do with the methodology of the clinical trials done by Lycos Therapeutics and the Multidisciplinary Association for Psychedelic Studies, or MAPS. Joining me today to talk about this are my guests. We have Sarah McNamee, a trial participant researcher at McGill University and a licensed psychotherapist based in Montreal, Quebec.